Medindia

X

CVBT Opens Two Additional Sites for Patient Enrollment for Phase II Heart Trial

Friday, December 12, 2008 General News J E 4
Advertisement
LAS VEGAS, Dec. 11 CardioVascular BioTherapeutics, Inc. (OTC Bulletin Board: CVBT) announced today that two additional hospitals in the United States opened for patient enrollment for its ACORD Phase II clinical trial for the treatment of severe coronary heart disease. The sites are Minneapolis Heart Institute Foundation in Minneapolis MN, and Princeton Baptist Medical Center in Birmingham AL.



Mercy Hospital Fairfield (Ohio) and The Christ Hospital in Cincinnati, Ohio were first to open for enrollment in early September, and are working in collaboration to screen and treat patients in the trial.



CVBT now has three sites open for patient enrollment.



About CardioVascular BioTherapeutics

CVBT (OTCBB: CVBT) is a biopharmaceutical company developing human FGF-1 for cardiovascular diseases characterized by inadequate blood flow to a tissue or organ. In addition to the ACORD trial it is conducting in patients with severe coronary heart disease, the company has two FDA-authorized clinical trials in the areas of impaired wound healing seen in diabetics and in patients suffering from peripheral artery disease of the legs. An additional study is being conducted in patients with chronic back pain who may have perfusion defects to their spine. For more information about CardioVascular BioTherapeutics, Inc. please visit www.cvbt.com.



About The ACORD Trial

CVBT's ACORD (Angiogenesis for the treatment of CORonary heart Disease) trial for the treatment of severe coronary heart disease will include four randomized, double-blind, placebo-controlled doses in approximately 120 patients with severe coronary heart disease. Thirty sites are expected to participate.



Media Contact: Allison Caplan, CardioVascular BioTherapeutics, Inc. (702) 839-7200, acaplan@cvbt.com Investor Contact: Amy Montano Gordon, CardioVascular BioTherapeutics, Inc. (702) 839-7220, investorrelations@cvbt.com

SOURCE CardioVascular BioTherapeutics, Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Peregrine Pharmaceuticals Mourns Loss of Chairman ...
S
Philip T. Sager, M.D., Joins NewCardio's Scientifi...